BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37969652)

  • 1. Cardiotoxicity of BRAF/MEK Inhibitors: A Longitudinal Study Incorporating Contemporary Definitions and Risk Scores.
    Glen C; Adam S; McDowell K; Waterston A; Tan YY; Petrie MC; Coats CJ; Lang NN
    JACC CardioOncol; 2023 Oct; 5(5):628-637. PubMed ID: 37969652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Features of trastuzumab-related cardiac dysfunction: deformation analysis outside left ventricular global longitudinal strain.
    Nhat GM; Hai NH; Duc VT; Tri HHQ; Hoa CN
    Front Cardiovasc Med; 2024; 11():1291180. PubMed ID: 38312233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer: Comparison With Echocardiography.
    Houbois CP; Nolan M; Somerset E; Shalmon T; Esmaeilzadeh M; Lamacie MM; Amir E; Brezden-Masley C; Koch CA; Thevakumaran Y; Yan AT; Marwick TH; Wintersperger BJ; Thavendiranathan P
    JACC Cardiovasc Imaging; 2021 May; 14(5):962-974. PubMed ID: 33248962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association of reduced global longitudinal strain with cancer therapy-related cardiac dysfunction among patients receiving cancer therapy.
    Laufer-Perl M; Arnold JH; Mor L; Amrami N; Derakhshesh M; Moshkovits Y; Sadeh B; Arbel Y; Topilsky Y; Rozenbaum Z
    Clin Res Cardiol; 2020 Feb; 109(2):255-262. PubMed ID: 31214777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis.
    Oikonomou EK; Kokkinidis DG; Kampaktsis PN; Amir EA; Marwick TH; Gupta D; Thavendiranathan P
    JAMA Cardiol; 2019 Oct; 4(10):1007-1018. PubMed ID: 31433450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early evaluation of subclinical cardiotoxicity in patients with lung cancer receiving immune checkpoint inhibitors by cardiovascular magnetic resonance: a prospective observational study.
    Liu J; Cao Y; Zhu K; Yao S; Yuan M; Kong X; Liu X; Li Y; Cui Y; Han X; Zhou X; Meng R; Shi H
    Quant Imaging Med Surg; 2022 Oct; 12(10):4771-4785. PubMed ID: 36185042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer Therapeutics-Related Cardiac Dysfunction among Patients with Active Breast Cancer: A Cardio-Oncology Registry.
    Laufer-Perl M; Mor L; Milwidsky A; Derakhshesh M; Amrami N; Moshkovits Y; Arnold J; Topilsky Y; Arbel Y; Rozenbaum Z
    Isr Med Assoc J; 2020 Sep; 22(9):564-568. PubMed ID: 33236555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardio-toxicity among patients with sarcoma: a cardio-oncology registry.
    Shamai S; Rozenbaum Z; Merimsky O; Derakhshesh M; Moshkovits Y; Arnold J; Topilsky Y; Arbel Y; Laufer-Perl M
    BMC Cancer; 2020 Jun; 20(1):609. PubMed ID: 32605637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninvasive Measures of Ventricular-Arterial Coupling and Circumferential Strain Predict Cancer Therapeutics-Related Cardiac Dysfunction.
    Narayan HK; French B; Khan AM; Plappert T; Hyman D; Bajulaiye A; Domchek S; DeMichele A; Clark A; Matro J; Bradbury A; Fox K; Carver JR; Ky B
    JACC Cardiovasc Imaging; 2016 Oct; 9(10):1131-1141. PubMed ID: 27085442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiotoxicity in metastatic melanoma patients treated with BRAF and MEK inhibitors in a real-world setting.
    Pedersen S; Larsen KO; Christensen AH; Svane IM; Zerahn B; Ellebaek E
    Acta Oncol; 2022 Jan; 61(1):45-51. PubMed ID: 34666597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic and Prognostic Value of Myocardial Work Indices for Identification of Cancer Therapy-Related Cardiotoxicity.
    Calvillo-Argüelles O; Thampinathan B; Somerset E; Shalmon T; Amir E; Steve Fan CP; Moon S; Abdel-Qadir H; Thevakumaran Y; Day J; Woo A; Wintersperger BJ; Marwick TH; Thavendiranathan P
    JACC Cardiovasc Imaging; 2022 Aug; 15(8):1361-1376. PubMed ID: 35926895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction.
    Demissei BG; Hubbard RA; Zhang L; Smith AM; Sheline K; McDonald C; Narayan V; Domchek SM; DeMichele A; Shah P; Clark AS; Fox K; Matro J; Bradbury AR; Knollman H; Getz KD; Armenian SH; Januzzi JL; Tang WHW; Liu P; Ky B
    J Am Heart Assoc; 2020 Jan; 9(2):e014708. PubMed ID: 31959034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular safety of rapidly accelerated fibrosarcoma B-type and/or mitogen-activated extracellular signal-regulated kinase inhibitors: A mixed approach combining a meta-analysis and a pharmacovigilance disproportionality analysis.
    Dolladille C; Font J; Bejan-Angoulvant T; Zaman K; Sassier M; Ezine E; Stefan A; Plane AF; Legallois D; Milliez P; Parienti JJ; Alexandre J
    Arch Cardiovasc Dis; 2020; 113(6-7):420-432. PubMed ID: 32418884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors:
    Glen C; Tan YY; Waterston A; Evans TRJ; Jones RJ; Petrie MC; Lang NN
    JACC CardioOncol; 2022 Mar; 4(1):1-18. PubMed ID: 35492830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The added value of the HFA/ICOS score in the prediction of chemotherapy-related cardiac dysfunction in breast cancer.
    Di Lisi D; Madaudo C; Faro DC; Rossetto L; Triolo OF; Losi V; Galassi AR; Monte IP; Novo G
    J Cardiovasc Med (Hagerstown); 2024 Mar; 25(3):218-224. PubMed ID: 38305134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Left ventricular ejection fraction decrease related to BRAF and/or MEK inhibitors in metastatic melanoma patients: A retrospective analysis.
    Berger M; Amini-Adlé M; Maucort-Boulch D; Robinson P; Thomas L; Dalle S; Courand PY
    Cancer Med; 2020 Apr; 9(8):2611-2620. PubMed ID: 32056395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Profile and Prognosis of a Real-World Cohort of Patients With Moderate or Severe Cancer Therapy-Induced Cardiac Dysfunction.
    Esteban-Fernández A; Carvajal Estupiñan JF; Gavira-Gómez JJ; Pernas S; Moliner P; Garay A; Sánchez-González Á; Fernández-Rozas I; González-Costello J
    Front Cardiovasc Med; 2021; 8():721080. PubMed ID: 34778393
    [No Abstract]   [Full Text] [Related]  

  • 19. Rationale and Design of the Strain Surveillance of Chemotherapy for Improving Cardiovascular Outcomes: The SUCCOUR Trial.
    Negishi T; Thavendiranathan P; Negishi K; Marwick TH;
    JACC Cardiovasc Imaging; 2018 Aug; 11(8):1098-1105. PubMed ID: 29909105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between regional left ventricular dysfunction and cancer-therapy-related cardiac dysfunction.
    Saijo Y; Kusunose K; Okushi Y; Yamada H; Toba H; Sata M
    Heart; 2020 Nov; 106(22):1752-1758. PubMed ID: 32209616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.